ABCG2 and neoplasm: Several clinical trials were prematurely terminated due to unexpected side effects, toxicity from adverse interaction with anticancer drugs, poor solubility, and limitations in the design of the studies (e.g., the patients were not selected based on tumor expression of ABC transporters, the absence of clinically validated imaging assays to detect ABC transporter function, etc.)[26,27].